{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:27:54Z","timestamp":1786933674706,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.tox.2022.153256","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T21:40:22Z","timestamp":1657575622000},"page":"153256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury"],"prefix":"10.1016","volume":"476","author":[{"given":"Yuanjie","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin\u2019an","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tox.2022.153256_bib1","first-page":"50","article-title":"Complex approach to xenobiotics hepatotoxicity testing using a microfluidic system[J]. Bulletin Experimental Biology","volume":"161","author":"Alexandrova","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.tox.2022.153256_bib2","article-title":"Thomas, et al. Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance[J]","author":"Anika","year":"2017","journal-title":"Hum. Cell"},{"issue":"1","key":"10.1016\/j.tox.2022.153256_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.[J]","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.tox.2022.153256_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/14728222.10.3.409","article-title":"FXR: a target for cholestatic syndromes?[J]","volume":"10","author":"Cai","year":"2006","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.tox.2022.153256_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbrc.2018.02.030","article-title":"First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform","volume":"497","author":"Cao","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tox.2022.153256_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00204-015-1473-1","article-title":"Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity[J]","volume":"89","author":"Chen","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.tox.2022.153256_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.taap.2009.06.022","article-title":"Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice[J]","volume":"240","author":"Chen","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2022.153256_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.toxlet.2020.01.018","article-title":"Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin[J]","volume":"322","author":"Combrink","year":"2020","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tox.2022.153256_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","article-title":"Developments in bile salt based therapies: A critical overview[J]","volume":"161","author":"Donkers","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.tox.2022.153256_bib10","first-page":"87","article-title":"Isoniazid hepatotoxicity with clinical and histopathology correlate[J]","volume":"44","author":"Gourishankar","year":"2014","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.tox.2022.153256_bib11","first-page":"1396","article-title":"Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?[J]","volume":"69","author":"Haan","year":"2018","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.tox.2022.153256_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/toxsci\/kfw098","article-title":"Pyrazinamide induced rat cholestatic liver injury through inhibition of FXR regulatory effect on bile acid synthesis and transport[J]","volume":"152","author":"Hong-Li","year":"2016","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.tox.2022.153256_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/toxsci\/69.2.424","article-title":"Cellular toxicity of hydrazine in primary rat hepatocytes.[J]","volume":"69","author":"Hussain","year":"2002","journal-title":"Toxicol. Sci."},{"issue":"4","key":"10.1016\/j.tox.2022.153256_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis[J]","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.tox.2022.153256_bib15","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/ajcn\/nqz036","article-title":"Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a model for end-stage intestinal failure (MESIF risk score)[J]","volume":"109","author":"Koelfat Kiran","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"issue":"7\u20138","key":"10.1016\/j.tox.2022.153256_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/00498250802040584","article-title":"Bile acid transporters in health and disease[J]","volume":"38","author":"Kosters","year":"2008","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.tox.2022.153256_bib17","first-page":"527","article-title":"Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs[J]. Expert Opinion Drug Metabolism","volume":"16","author":"Liu","year":"2020","journal-title":"Toxicology"},{"issue":"3\u20134","key":"10.1016\/j.tox.2022.153256_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2011.11.032","article-title":"Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes[J]","volume":"416","author":"Ogimura","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tox.2022.153256_bib19","unstructured":"Organization W.H., 2010, Treatment of tuberculosis:guidelines[J]."},{"key":"10.1016\/j.tox.2022.153256_bib20","unstructured":"Organization W.H., 2020, Global TB Report[J]."},{"issue":"5","key":"10.1016\/j.tox.2022.153256_bib21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1053\/j.gastro.2018.07.031","article-title":"Solute carrier organic anion transporter family member 3A1 is a bile acid efflux transporter in cholestasis[J]","volume":"155","author":"Pan","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.tox.2022.153256_bib22","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3390\/cells10081846","article-title":"Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury[J]","volume":"1010","author":"Petrescu","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.tox.2022.153256_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1101\/gad.184788.111","article-title":"Endocrine fibroblast growth factors 15\/19 and 21: from feast to famine[J]","volume":"26","author":"Potthoff","year":"2012","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.tox.2022.153256_bib24","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1248\/bpb.b18-00028","article-title":"Zhang, et al. Dysregulation of BSEP and MRP2 may play an important role in isoniazid-induced liver injury via the SIRT1\/FXR pathway in rats and HepG2 cells[J]","volume":"41","author":"Qu","year":"2018","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.tox.2022.153256_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management[J]","volume":"3","author":"Ramappa","year":"2013","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"4","key":"10.1016\/j.tox.2022.153256_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/0960327117705426","article-title":"Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid[J]","volume":"37","author":"Rawat","year":"2018","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.tox.2022.153256_bib27","first-page":"1072","article-title":"Rifampin-induced release of hydrazine from isoniazid[J]","author":"Sarma","year":"1986","journal-title":"Am. Rev. Respir. Dis."},{"issue":"1","key":"10.1016\/j.tox.2022.153256_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00011-014-0780-y","article-title":"Role of farnesoid X receptor in inflammation and resolution[J]","volume":"64","author":"Shaik","year":"2015","journal-title":"Inflamm. Res."},{"issue":"4","key":"10.1016\/j.tox.2022.153256_bib29","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1128\/AAC.01866-12","article-title":"A novel mechanism underlies the hepatotoxicity of pyrazinamide[J]","volume":"57","author":"Shih","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.tox.2022.153256_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.xphs.2020.10.064","article-title":"Transient, Tunable Expression of NTCP and BSEP in MDCKII Cells for Kinetic Delineation of the Rate-Determining Process and Inhibitory Effects of Rifampicin in Hepatobiliary Transport of Taurocholate[J]","volume":"110","author":"Si","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tox.2022.153256_bib31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fmed.2020.00544","article-title":"and FXR: Novel Targets for Liver","volume":"7","author":"Stofan","year":"2020","journal-title":"Dis. [J. ]. Front. Med."},{"key":"10.1016\/j.tox.2022.153256_bib32","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.xphs.2016.01.013","article-title":"Establishment of a Drug-Induced, Bile Acid-Dependent Hepatotoxicity Model Using HepaRG Cells.[J]","author":"Susukida","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.tox.2022.153256_bib33","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases.[J]","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.tox.2022.153256_bib34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review[J]","volume":"23","author":"Tostmann","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tox.2022.153256_bib35","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1097\/01.mcg.0000155551.37266.26","article-title":"Molecular regulation of hepatobiliary transport systems: Clinical implications for understanding and treating cholestasis[J]","volume":"39","author":"Trauner","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.tox.2022.153256_bib36","first-page":"79","article-title":"Review of pyridoxal phosphate and the transaminases in liver disease[J]","volume":"16","author":"Vanderlinde","year":"1986","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"8","key":"10.1016\/j.tox.2022.153256_bib37","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","article-title":"Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring[J]","volume":"72","author":"Verbeeck","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2022.153256_bib38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2009.05.012","article-title":"New molecular insights into the mechanisms of cholestasis[J]","volume":"51","author":"Wagner","year":"2009","journal-title":"J. Hepatol."},{"issue":"02","key":"10.1016\/j.tox.2022.153256_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0030-1253225","article-title":"Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis[J]","volume":"30","author":"Wagner","year":"2010","journal-title":"Semin. Liver Dis."},{"issue":"7","key":"10.1016\/j.tox.2022.153256_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrgastro.2014.32","article-title":"Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy[J]","volume":"11","author":"Walters","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tox.2022.153256_bib41","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fphar.2020.01084","article-title":"Mechanism of hydrophobic bile acid-induced hepatocyte injury and drug discovery[J]","volume":"11","author":"Wei","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.tox.2022.153256_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/toxres\/tfaa015","article-title":"Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k\/Akt inhibition[J]","volume":"9","author":"Xu","year":"2020","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.tox.2022.153256_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115134","article-title":"Pyridoxal isonicotinoyl hydrazone inhibition of FXR is involved in the pathogenesis of isoniazid-induced liver injury[J]","volume":"402","author":"Zhang","year":"2020","journal-title":"Toxicol. Appl. Pharm."},{"issue":"9","key":"10.1016\/j.tox.2022.153256_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbt.22369","article-title":"Quercetin protected against isoniazide\u2010induced HepG2 cell apoptosis by activating the SIRT1\/ERK pathway[J]","volume":"33","author":"Zhang","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X22001688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X22001688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:52:10Z","timestamp":1759535530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X22001688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"alternative-id":["S0300483X22001688"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2022.153256","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2022.153256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153256"}}